Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).

Current securities

1. Regulation FD DisclosureSep 24, 2026
2. 10-Q filingAug 11, 2026
3. Results of Operations and Financial ConditionAug 11, 2026
4. Entry into a Material Definitive Agreement · Regulation FD DisclosureJul 27, 2026
5. Entry into a Material Definitive AgreementJul 9, 2026